Trial site
K2 Medical Research WINTER GARDEN
Clermont, Florida 34711, United StatesNot linked to an institution yet
- 11running trials
- 4closed trials
The trials here
What the 15 trials at this site are about, from their registry records.
- Phase
- Phase 310 trials
- Phase 24 trials
- Phase 1/21 trial
- Status
- Recruiting6 trials
- Active, not recruiting5 trials
- Completed4 trials
- Lead sponsor
- Hoffmann-La Roche5 trials
- Eli Lilly and Company3 trials
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company2 trials
- Novo Nordisk A/S2 trials
- Boehringer Ingelheim1 trial
- and 2 more
Running trials
Recruiting
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
NCT07602582· Phase 3· Eli Lilly and Company· Source
Contact: Christopher Galloway (principal investigator)
Active, not recruiting
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07170150· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028· Phase 3· Eli Lilly and Company· Source
Contact: Beatriz Colon (principal investigator)
Recruiting
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
NCT07177352· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
NCT06965413· Phase 2· Hoffmann-La Roche· Source
Active, not recruiting
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153· Phase 3· Eli Lilly and Company· Source
Recruiting
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Active, not recruiting
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
NCT06544616· Phase 2· Janssen Pharmaceutica N.V., Belgium· Source
Recruiting
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Contact: Christopher Galloway, Site 1048
Recruiting
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
NCT05511363· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Contact: Christopher Galloway, Site 1048
Active, not recruiting
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
NCT04639050· Phase 1/2· Hoffmann-La Roche· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error